This HTML5 document contains 167 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://dx.doi.org/10.1038/
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36644465
rdf:type
wikibase:Item
schema:description
2002年论文 artículu científicu espublizáu en 2002 naučni članak مقالة علمية نشرت في مايو 2002 scientific article published on May 2002 2002년 논문 2002年の論文 artikel ilmiah บทความทางวิทยาศาสตร์ videnskabelig artikel tudományos cikk 2002年論文 article científic 2002年論文 wetenschappelijk artikel научни чланак artykuł naukowy artikulong pang-agham scientific article published on May 2002 научна статия գիտական հոդված հրատարակված 2002 թվականի մայիսին artigo científico 2002年论文 2002年论文 scienca artikolo мақолаи илмӣ article scientific articolo scientifico bài báo khoa học 2002年論文 article scientifique মে ২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitenskapelig artikkel 2002年论文 artículo científico publicado en 2002 מאמר מדעי наукова стаття, опублікована в травні 2002 vedecký článok artigo científico 2002年論文 vitskapeleg artikkel vědecký článek επιστημονικό άρθρο научни чланак научная статья 2002年論文 2002 nî lūn-bûn artigo científico wissenschaftlicher Artikel vetenskaplig artikel articol științific 2002年论文 teaduslik artikkel bilimsel makale სამეცნიერო სტატია artikull shkencor scientific article published on May 2002 2002年论文 tieteellinen artikkeli
p:P577
wds:Q36644465-5F204B1A-CA0D-49C5-821C-A3CA270B1DCF
wdt:P577
2002-05-01T00:00:00Z
p:P407
wds:Q36644465-05302BD7-0A57-4A92-AB93-38E370A66A7B
wdt:P407
wd:Q1860
p:P2888
wds:Q36644465-FDA32E84-2C71-433D-A7A0-03E20686179B
wdt:P2888
n12:sj.bjc.6600261
p:P2860
wds:Q36644465-52998E4B-1773-4582-A6B6-002295CDB10E wds:Q36644465-5949E043-A19B-4B33-8F4F-CFF9C9E857C9 wds:Q36644465-7F92456A-7BE8-4113-A94F-5852FB1023D4 wds:Q36644465-37197A62-8BAB-4184-9D49-192B8E6169D0 wds:Q36644465-42F2BF4D-2165-4034-946F-EB1933CC47E0 wds:Q36644465-488E9760-3E94-4A81-AAAF-740D3A5388E1 wds:Q36644465-02D71A08-C6BE-4754-851B-371935E0F119 wds:Q36644465-037A4B59-9C18-499F-8B85-46382DA1218E wds:Q36644465-0C4AD061-5921-4AD5-8603-B6C8C0873F90 wds:Q36644465-14302737-104F-4D59-8C27-40FF6D0BFB45 wds:Q36644465-EBADD70D-609B-4F12-A7A7-795FFC2FF220 wds:Q36644465-BEC82EA0-4B77-4698-B642-3322092FC88C wds:Q36644465-BF9E2698-AC19-47DE-9862-A898F759EC07 wds:Q36644465-C85299C4-507C-453B-AA26-BE5A5A86D622 wds:Q36644465-CF4C0C3E-9719-4116-865C-5B2EE6FC506A wds:Q36644465-A18CEDCA-4281-41A9-8EBC-517550E37103 wds:Q36644465-ACD44211-F6AD-42EF-AB8F-ED8C2AB55D7D wds:Q36644465-80594119-1811-4B5F-9BC1-BD60006B29B2
wdt:P2860
wd:Q42551612 wd:Q40817780 wd:Q73446651 wd:Q33491991 wd:Q59647346 wd:Q33686026 wd:Q33704933 wd:Q36892107 wd:Q33704928 wd:Q77350843 wd:Q27863454 wd:Q54077157 wd:Q33855276 wd:Q73544195 wd:Q54090352 wd:Q40915962 wd:Q72824407 wd:Q73648001
p:P2093
wds:Q36644465-26C8AC08-157D-40E0-85F5-76B35345A5DE wds:Q36644465-BB6D693B-FC0B-4B4E-B66F-35ECAD4A3233 wds:Q36644465-AA433033-6DF4-46F2-988A-9964AAB0AA81 wds:Q36644465-911E2D00-A8EC-49B5-94B2-027B121600FF wds:Q36644465-849F72C2-2D33-4A87-91EC-1A82775073C2 wds:Q36644465-FA02CADE-B679-4709-906C-5AA7B6E84AD7 wds:Q36644465-FD3F0BE8-8372-45AC-A431-A62F282B40F9 wds:Q36644465-CF4CE1AE-1A17-465D-83E6-F9DDBDD31FAD wds:Q36644465-BF4A6B1C-4CD4-4684-A5FF-2E7703D616CE
wdt:P2093
P Eisenberg D Melnychuk D C Talbot S Van Belle S Ackland B Osterwalder S Laws H-U Burger S M O'Reilly
rdfs:label
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
skos:prefLabel
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
schema:name
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
p:P50
wds:Q36644465-888A220C-CCAC-42E2-9D28-226C7E0B87E8 wds:Q36644465-9CCD4843-B7F2-4E12-9986-522E536AC9CE wds:Q36644465-FD7D1059-A23F-44D0-968D-F4986D2D8D39
wdt:P50
wd:Q48048503 wd:Q57023242 wd:Q38290512
p:P1476
wds:Q36644465-D1BEFDD8-CBA9-4B61-A3B0-4366C178BE46
wdt:P1476
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
p:P304
wds:Q36644465-B3C39A5E-504B-431A-9166-5A55F74BE0A5
wdt:P304
1367-1372
p:P31
wds:Q36644465-A487FD98-DE2C-4FDC-8388-8C1A653F5326
wdt:P31
wd:Q13442814
p:P921
wds:Q36644465-8B6462DE-CCE2-4F09-A40E-6C9E0685094A wds:Q36644465-868EAC72-D4E8-4B27-B476-E078D427BF47 wds:Q36644465-637E3364-68C1-4EE7-8B4E-E293F712BB3E wds:Q36644465-0F5AEC96-6CFA-4BEC-BECC-F0DC7938E0EB
wdt:P921
wd:Q42824440 wd:Q423762 wd:Q420207 wd:Q128581
p:P698
wds:Q36644465-2EC7C122-1136-46D1-A1EE-9888C03B6011
wdtn:P698
n13:11986765
wdt:P698
11986765
p:P1433
wds:Q36644465-5F76002D-381B-40A4-A641-E4272AFCC729
wdt:P1433
wd:Q326309
p:P433
wds:Q36644465-488564AD-8B4B-4FD0-9F56-6C3EF7E1E184
p:P478
wds:Q36644465-B7EC21EB-4FDA-4E33-A6CE-679C116CA2CE
wdt:P433
9
wdt:P478
86
p:P356
wds:Q36644465-837EB5E3-EFC9-48DD-8FC7-86702E657C58
wdtn:P356
n11:SJ.BJC.6600261
wdt:P356
10.1038/SJ.BJC.6600261
p:P8608
wds:Q36644465-1DDF48A3-0D48-4EF7-9BAA-17E110676368
wdt:P8608
release_mi37v4xz5fc35o6eqm6vhbnm2i
p:P5875
wds:Q36644465-3710E0FC-0579-43F0-91AC-ACFFF1733D29
wdt:P5875
11382932
p:P932
wds:Q36644465-4B024D11-F0FD-49AD-A9E2-349DEC987621
wdt:P932
2375384